What is claimed is:

- 1. An isolated nucleic acid comprising any one of the following:
 - (a) a nucleic acid sequence encoding a polypeptide of SEQ IDNO: 2;
 - (b) a nucleic acid sequence at least 90% identical to the nucleic acid sequence of (a) above;
 - (c) a nucleic acid encoding a polypeptide wherein the polypeptide has conservative amino acid substitutions to the polypeptide of SEQ ID NO: 2; or
 - (d) a fragment of the nucleic acid sequence of (a), (b) or (c) above wherein the fragment comprises at least 20 nucleotides.
- 2. The nucleic acid of claim 1, wherein said nucleic acid is selected from the group consisting of DNA and RNA.
- 3. The nucleic acid of claim 1, wherein said nucleic acid comprises an open reading frame that encodes a polypeptide of SEQ ID NO: 2 or its complement, or a mutant or variant thereof.
- 4. The nucleic acid of claim 1, wherein said nucleic acid comprises a nucleic acid sequence which is SEQ ID NO: 1 or its complement.
- 5. The nucleic acid of claim 3 wherein said nucleic acid encodes a mature form of the polypeptide comprising an amino acid of SEQ ID NO: 2.
- 6. The nucleic acid of claim 4 wherein said nucleic acid encodes a polypeptide comprising an amino acid of SEQ ID NO: 2, a mutant or variant thereof.

Attorney Ref.: 15966-551 CON-S2 (Cura-51 CON-S2)

- 7. An oligonucleotide sequence that is complementary to and hybridizes under stringent conditions with the nucleic acid of claim 1.
- 8. The oligonucleotide sequence of claim 7 that is complementary to at least a portion of the nucleotide sequence of SEQ ID NO: 1.
- An isolated nucleic acid comprising a nucleotide sequence complementary to at least a portion of a nucleic acid according to claim 3.
- 10. A vector comprising the nucleic acid of claim 1.
- 11. A cell comprising the vector of claim 10.
- 12. The cell of claim 11 wherein said cell is a prokaryotic or eukaryotic cell comprising the nucleic acid sequence which is SEQ ID NO: 1, its complement, or a mutant or variant thereof.
- 13. A pharmaceutical composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable carrier.
- 14. A process for producing a polypeptide encoded by the nucleic acid of claim 1, said process comprising:
 - a) providing the cell of claim 11;
 - b) culturing said cell under conditions sufficient to express said polypeptide; and
 - c) recovering said polypeptide,
 - thereby producing said polypeptide.
- 15. The process of claim 14 wherein said cell is a prokaryotic or eukaryotic cell.
- 16. A process for identifying a compound that binds the nucleic acid of claim 1, the process comprising:

BURESHO BURUSUE

Attorney Ref.: 15966-551 CON-S2 (Cura-51 CON-S2)

- a) contacting said nucleic acid with a compound; and
- b) determining whether said compound binds said nucleic acid sequence.
- 17. The compound identified by the process of claim 16.